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Brief Definit ive Report
Multiple sclerosis (MS) is a progressive, neurode-
generative disease of the central nervous system 
(CNS) in which myelin destruction leads to 
motor and sensory function loss. A majority of 
MS patients present with remitting-relapsing 
disease, characterized by periods of demyelin-
ation followed by partial recovery (Steinman, 
2009). Despite the presence of oligodendrocyte 
progenitor cells (OPCs) in MS lesions (Chang 
et al., 2000, 2002), remyelination gradually fails 
while demyelination continues, contributing to 
progressive clinical deterioration (Compston and 
Coles, 2002). The mechanisms underlying CNS 
repair are poorly understood; thus, there are cur-
rently no therapies to augment remyelination 
(Franklin and Ffrench-Constant, 2008).
Recent data indicate that the chemokine 
CXCL12 regulates OPC-mediated remyelin-
ation (Carbajal et al., 2010; Patel et al., 2010, 
2012). CXCL12 and its receptor, CXCR4, are 
indispensable for the plasticity of the CNS 
(Zou et al., 1998; Zhu et al., 2009) as they are 
necessary for proper migration and survival of 
OPCs (Dziembowska et al., 2005). Blockade of 
CXCR4-CXCL12 signaling limits OPC matu-
ration during remyelination (Carbajal et al., 2010; 
Patel et al., 2010). An alternative CXCL12 scav-
enger receptor, CXCR7/ACKR3 (CXCR7), 
sequesters ligand for degradation, regulat-
ing CXCL12-mediated activation of CXCR4 
(Boldajipour et al., 2008; Naumann et al., 2010; 
Cruz-Orengo et al., 2011b). In vitro studies of 
OPCs reveal functional expression of CXCR7 
(Göttle et al., 2010), suggesting that it may 
regulate CXCR4 activation during differentia-
tion, as is observed for other neural progenitors 
(Boldajipour et al., 2008). The in vivo role of 
CXCR7 within the demyelinated CNS remains 
largely unexamined.
CORRESPONDENCE  
Robyn S. Klein:  
rklein@dom.wustl.edu
Abbreviations used: CC, corpus 
callosum; CNS, central nervous 
system; CPZ, cuprizone; 
CXCR7, CXCR7/ACKR3; 
MBP, myelin basic protein; 
MOG, myelin oligodendrocyte 
glycoprotein; MS, multiple 
sclerosis; OPC, oligodendrocyte 
progenitor cell.
Targeting CXCR7/ACKR3 as a therapeutic 
strategy to promote remyelination  
in the adult central nervous system
Jessica L. Williams,1 Jigisha R. Patel,1 Brian P. Daniels,3 and  
Robyn S. Klein1,2,3
1Department of Internal Medicine, 2Department of Pathology and Immunology, and 3Department of Anatomy  
and Neurobiology, Washington University School of Medicine, St. Louis, MO 63110
Current treatment modalities for the neurodegenerative disease multiple sclerosis (MS) use 
disease-modifying immunosuppressive compounds but do not promote repair. Although 
several potential targets that may induce myelin production have been identified, there has 
yet to be an approved therapy that promotes remyelination in the damaged central nervous 
system (CNS). Remyelination of damaged axons requires the generation of new oligoden-
drocytes from oligodendrocyte progenitor cells (OPCs). Although OPCs are detected in MS 
lesions, repair of myelin is limited, contributing to progressive clinical deterioration. In the 
CNS, the chemokine CXCL12 promotes remyelination via CXCR4 activation on OPCs, result-
ing in their differentiation into myelinating oligodendrocytes. Although the CXCL12 scav-
enging receptor CXCR7/ACKR3 (CXCR7) is also expressed by OPCs, its role in myelin repair 
in the adult CNS is unknown. We show that during cuprizone-induced demyelination, in vivo 
CXCR7 antagonism augmented OPC proliferation, leading to increased numbers of mature 
oligodendrocytes within demyelinated lesions. CXCR7-mediated effects on remyelination 
required CXCR4 activation, as assessed via both phospho-S339-CXCR4–specific antibodies 
and administration of CXCR4 antagonists. These findings identify a role for CXCR7 in OPC 
maturation during remyelination and are the first to use a small molecule to therapeuti-
cally enhance myelin repair in the demyelinated adult CNS.
© 2014 Williams et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/ 
by-nc-sa/3.0/).
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1999; Banisadr et al., 2003; Calderon et al., 2006; McCandless 
et al., 2008; Schönemeier et al., 2008). Given that spatiotem-
poral expression of CXCL12 is critical to its function during 
CNS injury and its levels are regulated by CXCR7, we sought 
to identify cellular sources of CXCR7 during demyelination. 
After 3 wk of CPZ intoxication, CXCR7 was expressed by 
OPCs (45.9 ± 8.0%) and activated astrocytes (43.1 ± 10.5%; 
Fig. 1 F). However, after 6 wk of CPZ, CXCR7 was expressed 
by multiple cell types including OPCs (28.2 ± 3.1%), acti-
vated astrocytes (30.4 ± 1.9%), endothelial cells (15.8 ± 4.2%), 
and axons (22.2 ± 5.7%). CXCR7 expression was minimally 
detected within activated microglia (1.3 ± 0.4%; Fig. 1 G). Of 
note, 6.2 ± 1.8% and 4.3 ± 0.7% of OPCs expressed CXCR7 
after 3 and 6 wk of CPZ treatment, respectively.
CXCR7 regulates levels of CXCL12 protein  
and CXCR4 signaling in OPCs
The high levels of expression of CXCR7 during demyelin-
ation suggested it might serve to regulate extracellular levels of 
CXCL12. To test this, we administered a CXCR7 antagonist, 
CCX771 (Cruz-Orengo et al., 2011b), versus a vehicle control 
(10% captisol) to mice during the first or final 3 wk of CPZ-
mediated demyelination occurring over a 6-wk period (Fig. 2, 
A and C). Although CXCL12 protein levels did not differ in 
vehicle versus CCX771-treated mice after the first 3 wk of 
treatment (Fig. 2 B), CXCR7 antagonism during the latter 
3 wk of CPZ resulted in increased levels of CXCL12 (Fig. 2, 
D and F). Levels of ligand-activated CXCR4 (phospho-S339-
(p)CXCR4) in OPCs were also increased in the CCX771-
treated CC compared with vehicle-treated controls during 
demyelination (Fig. 2 E). These data suggest that the CCX771-
mediated increase in CXCL12 promotes CXCR4 activation 
within OPCs. Because an increase in CXCL12 mRNA ex-
pression was not observed in the presence of CCX771 (Fig. 2 G) 
but, rather, a decrease in CXCL12-mCherry internalization in 
astrocytes was seen in the presence of CCX771 (Fig. 2 H), the 
mechanism of CCX771-mediated CXCL12 regulation is likely 
dependent on decreased degradation of available CXCL12 
protein. The lack of effect of CCX771 on levels of CXCL12 at 
the 3-wk time point is likely due to the low levels of CXCR7 
observed during the first 3 wk of CPZ exposure (Fig. 1 B). 
These findings during CNS injury are reminiscent of molecu-
lar events that occur during development wherein CXCL12 
provides localization cues to neural progenitors, regulating 
CXCR4 signaling in precursor cells in proliferative zones 
within the brain (Klein and Rubin, 2004).
CXCR7 regulates the proliferation and maturation  
of OPCs during demyelination
Because proliferation of OPCs peaks between 3 and 4 wk of 
CPZ exposure (Arnett et al., 2001), we determined whether 
CXCR7 inactivation impacted OPC proliferation during de-
myelination. To evaluate the influence of CXCR7 on OPC 
proliferation, mice were fed CPZ-infused feed and treated 
with CCX771, followed by BrdU injections every 8 h for 4 d 
Our previous studies demonstrate that CXCR7 targeting 
during experimental autoimmune encephalomyelitis (EAE) 
decreases disease severity as a result of altered T cell localiza-
tion in the perivascular space, restricting autoreactive leuko-
cyte trafficking into the CNS parenchyma (Cruz-Orengo 
et al., 2011b). In vivo analysis revealed that CXCR7 antago-
nism during EAE also preserves axonal integrity (Cruz-Orengo 
et al., 2011a). In the current study, we investigated the role 
of CXCR7 during demyelination and remyelination in the 
context of cuprizone (CPZ) exposure. During CPZ-mediated 
myelin injury, OPCs migrate to and proliferate within the 
caudal corpus callosum (CC) to initiate repair (Patel et al., 
2010). After cessation of CPZ, OPCs differentiate into mature 
oligodendrocytes and remyelination is achieved within weeks 
(Lindner et al., 2008). We report that during demyelination, 
CXCR7 expression is significantly up-regulated, returning 
to baseline during remyelination. Treatment with CCX771, 
a specific CXCR7 antagonist (Cruz-Orengo et al., 2011b), 
during demyelination and peak CXCR7 expression led to 
increased levels of CXCL12, enhanced CXCR4 activation 
and augmented differentiation of OPCs, resulting in increased 
numbers of mature oligodendrocytes within the demyelin-
ated CC. The enhanced remyelination observed in CCX771-
treated animals was abrogated by treatment with the specific 
CXCR4 antagonist AMD3100 (Hatse et al., 2002). These data 
indicate that CXCR7 regulates CXCL12-CXCR4–mediated 
CNS myelin repair and may therefore serve as a valuable thera-
peutic target to promote remyelination in the demyelinated 
adult CNS.
RESULTS AND DISCUSSION
Expression of CXCL12 and its receptors, CXCR4 and CXCR7, 
is increased during repair of myelin within the adult CNS
To evaluate the effects of demyelination on CXCR7 expres-
sion, we evaluated the corpus callosum of CPZ-exposed mice 
in which one copy of the CXCR7 gene was replaced with 
cDNA encoding enhanced GFP (CXCR7GFP/+; Cruz-Orengo 
et al., 2011b) at 0, 3, and 6 wk after CPZ exposure and at 10 d 
after CPZ cessation. During demyelination, as myelin basic 
protein (MBP) levels decrease over time (Fig. 1 A), CXCR4, 
CXCR7, and CXCL12 levels were significantly increased 
within the CC (Fig. 1, B–D), peaking before remyelination. 
Importantly, during remyelination, CXCR7 levels return to 
those observed in naive animals (Fig. 1 B), while CXCR4 and 
CXCL12 levels remain elevated (Fig. 1, C and D). As previ-
ously observed, OPC numbers dramatically increase within 
the demyelinated CC after 3–6 wk of CPZ intoxication (Patel 
et al., 2010; Fig. 1 E) and diminish, as expected, during remy-
elination (Fig. 1 E). In accordance with prior studies, the up-
regulation of CXCR7 exclusively during demyelination is 
consistent with its role in tightly regulating CXCR4 activ-
ity in response to extracellular CXCL12 during CNS insult 
(Schönemeier et al., 2008).
Several CNS cell types are known to express CXCL12 
during injury and mediate pluripotent effects (Bajetto et al., 
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significant increase in the number of proliferating OPCs com-
pared with vehicle-treated controls (Fig. 3 B, inset). Addi-
tionally, we observed similar MBP levels after simultaneous 
CPZ and vehicle or CCX771 treatment, suggesting demy-
elination was similar in the two treatment groups (Fig. 3 C). 
Numbers of proliferating OPCs in mice treated with vehicle 
(Fig. 3 A), as previously described (Patel et al., 2012). After the 
3-wk treatment period, areas of hypercellularity in CXCR7 
antagonist-treated animals were evident within the dorsal 
hippocampal commissure, which were absent in mice treated 
with vehicle (Fig. 3 B, white box). Analysis of BrdU+NG2+ 
OPC numbers revealed that CXCR7 antagonism led to a 
Figure 1. Chemokine expression and OPC 
population patterns throughout demyelina-
tion and remyelination. (A–E) Confocal IHC 
analysis of the CC of naive CXCR7GFP/+ mice 
and after 3 or 6 wk of CPZ ingestion and after 
10 d remyelination. Sections were stained for 
MBP (A), GFP (CXCR7; B), CXCR4 (C), CXCL12 
(D), and NG2 (E). The mean positive area was 
analyzed for naive mice (N), mice fed CPZ for 
3 or 6 wk, and mice fed CPZ for 6 wk and then 
a standard diet for a 10-d recovery period (R). 
(F and G) Confocal IHC analysis of the CC of 
CXCR7GFP/+ mice after 3 wk (F) or 6 wk (G) of 
CPZ ingestion. Sections were stained for GFP 
(green) in combination with NG2, GFAP, Iba-1, 
CD31, and NFH (red). The area of co-localiza-
tion was analyzed via Volocity image analysis 
software and normalized to the total GFP+ 
area. Representative images are shown and 
quantitative data were collected from 3 sec-
tions per mouse (n = 4–8 mice/group) across 
2 independent experiments with results shown 
as fold change compared with naive ± SEM. 
Insets = isotype control (IC). Bars, 25 µm.  
*, P < 0.05; **, P < 0.01.
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compared with those that received vehicle. Consistent with 
this, levels of myelin oligodendrocyte glycoprotein (MOG) and 
myelin staining were increased in CCX771-treated mice 
compared with those treated with vehicle (Fig. 3 I), al-
though this did not reach statistical significance, presumably 
because of the continued presence of CPZ. Furthermore, 
using an antibody that detects MBP69-86, a cryptic epitope 
which is normally unavailable for antibody binding in in-
tact myelin (Matsuo et al., 1997), we found that mice treated 
with CCX771 revealed significantly less exposed MBP69-86 
during CXCR7 antagonism (Fig. 3 J). These observations 
were confirmed using standard histological myelin staining 
or CCX771 for the final 3 wk of CPZ exposure (Fig. 3 D), as 
assessed via IHC for PDGFR+Ki-67+ cells, were too few to 
quantitate (unpublished data).
Because CXCR7 mediates the internalization of CXCL12 
(Fig. 2 H), thereby regulating CXCR4 activation in OPCs 
(Fig. 2 E), we hypothesized that therapeutic targeting of 
CXCR7 might impact OPC differentiation during demye-
lination. To test this, we administered CCX771 during the 
latter 3 wk of 6 wk of CPZ exposure (Fig. 3 D). Although 
there was a decrease in immature PDGFR+ cells (Fig. 3 F), 
we observed a significant increase in mature, GST+ oli-
godendrocytes (Fig. 3 H) in mice treated with CCX771 
Figure 2. CXCR7 regulates CXCL12 expression during CNS demyelination. (A) Timeline depicting the experimental design for mice exposed to CPZ 
and vehicle or CCX771 treatment for 3 wk. (B) Confocal IHC analysis on sections of the CC stained for CXCL12 after 3 wk of CPZ ingestion and daily injec-
tions of vehicle or CCX771. The mean positive area was analyzed for vehicle- (white bar) and CCX771-treated (black bar) mice. Representative images are 
shown and quantitative data were collected from 3 sections per mouse (n = 4–5 mice/group) across 2 independent experiments. Insets = isotype control 
(IC). Bar, 25 µm. (C) Timeline depicting the experimental design for mice exposed to CPZ for 6 wk and vehicle or CCX771 treatment for 3 wk. (D and E) Con-
focal IHC analysis of the CC was done on sections that were stained for CXCL12 (D) and p-CXCR4 and PDGFR (E). (F) CXCL12 protein levels within dis-
sected caudal CC of treated mice were determined by Western blot. Quantitation of relative CXCL12 versus -tubulin was performed (n = 4–5 mice/group). 
(G) Primary astrocytes were treated with the indicated doses of CCX771 and expression of CXCL12 was measured via qRT-PCR. Data are representative of  
2 independent experiments, each group in 5 replicates. (H) Astrocytes were treated for 2 h with a vehicle control (DMSO) or with 5 or 50 nM CCX771 after a 
4-h incubation with either CXCL12-mCherry or recombinant mCherry (25 ng/ml) in combination with vehicle or CCX771. The fold change in internalization 
was determined by confocal microscopy. Data are representative of 2 independent experiments, each group in 8 replicates with data shown as fold change 
over vehicle ± SEM. Inset = isotype control (IC). Bars, 10 µm. *, P ≤ 0.05; **, P ≤ 0.01; ***, P < 0.001.
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Figure 3. Inhibition of CXCR7 enhances OPC proliferation and maturation. (A) The depicted timeline represents the experimental design for mice 
given BrdU after vehicle or CCX771 treatment. (B and C) Confocal IHC analysis of the CC after 3 wk of CPZ ingestion and daily injections of vehicle or 
CCX771 s.c. (B) Sections of the CC delineated by the white box in B were stained for BrdU (green; B) and NG2 (red; B) or MBP (C). The mean number of 
BrdU+NG2+ cells/mouse was counted and mean positive areas of MBP immunostaining were analyzed across 3 sections for vehicle- (white bar) and 
CCX771-treated (black bar) mice. Representative images are shown and quantitative data were collected from 3 sections per mouse (n = 4–5 mice/group) 
across 2 independent experiments. Inset = isotype control (IC). Bars, 25 µm. (D) Timeline depicting the experimental design for mice exposed to CPZ for  
6 wk and vehicle or CCX771 treatment for 3 wk. (E–J) Confocal IHC analysis of the CC was performed on sections that were stained for NG2 (E), PDGFR (F), 
O4 (G), GST (H), MOG (I), and MBP69-86 (J). The mean positive areas of immunostaining were analyzed for mice treated with vehicle (white bar) or CCX771 
(black bar). Representative images are shown and quantitative data were collected from 3 sections per mouse (n = 8 mice/group) across 2 independent 
experiments with data shown as fold change over vehicle ± SEM. Inset = isotype control (IC); Bar, 25 µm. **, P < 0.01; ***, P < 0.001. (K) Eriochrome cya-
nine R staining of the CC for naive, vehicle- and CCX771-treated mice at 6 wk. Bars, 200 µm.
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Remyelination is regulated by CXCR7
To assess OPC maturation during remyelination, we fed mice 
a CPZ-infused diet for 6 wk, antagonizing CXCR7 during 
weeks 3–6. We then discontinued both the CPZ and CCX771 
(Fig. 3 K). These data suggest that CXCR7 regulates CXCR4 
signaling on OPCs, controlling the kinetics of their differen-
tiation and myelin recovery within injured white matter of 
the adult CNS.
Figure 4. CXCR7 restricts CXCR4-mediated OPC maturation. (A) The depicted timeline represents the experimental design for mice given CPZ for  
6 wk and captisol or CCX771 for 3 wk. After the CPZ/captisol or CCX771 treatments, mice were fed a standard chow and captisol and CCX771 injections 
were ceased as depicted by the red line. During this recovery period, mice received continuous infusion of saline or AMD3100 versus no treatment for 10 d. 
(B) Quantitative confocal imaging of immunostained CC sections for MOG, GST, and pCXCR4. Data are expressed as the mean positive area (MOG and 
pCXCR4) or mean number of cells (GST) for mice treated with captisol, CCX771 alone, CCX771 and saline, and CCX771 and AMD3100. Representative 
images are shown and quantitative data were collected from 3 sections per mouse (n = 5–10 mice/group) across 2 independent experiments with data 
shown as fold change over captisol ± SEM. Inset = isotype control (IC). Bar, 25 µm. *, P < 0.05; **, P < 0.01. (C) Eriochrome cyanine R staining on sections 
of the CC from captisol-, CCX771-, CCX771 and saline–, and CCX771 and AMD3100–treated mice. Bars, 200 µm. (D) Toluidine blue staining on sagittal 
sections of the CC from naive (left), captisol-treated (middle), and CCX771-treated (right) mice with digitally zoomed images (inset). Red arrows = 
demyelinated axons, yellow arrows = remyelinated axons. Bar, 10 µm. Representative images are shown (n = 4 mice/group).
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during CPZ-induced demyelination specifically reduces the 
number of proliferating, white matter-associated NG2+ OPCs 
(Patel et al., 2012). Here, our results demonstrate that CXCR7 
works to restrict CXCL12 availability, limiting the pool of 
OPCs in areas of demyelination. Hence, blocking CXCR7 
activity resulted in expansion of remyelination-competent 
cells that may participate in recovery.
Targeting of CXCR7 to regulate extracellular CXCL12 
and CXCR4 activation has significant implication for the 
treatment of chronic CNS demyelinating diseases such as MS. 
During MS pathogenesis, OPCs are more abundant on lesion 
borders versus normal-appearing white matter and are phe-
notypically quiescent, lacking markers of proliferation and 
maturation (Wolswijk, 1998; Kuhlmann et al., 2008). Further-
more, astrocyte-associated CXCL12 is expressed on chronic 
lesion borders at low to moderate levels compared with in 
active lesions (Calderon et al., 2006; Kuhlmann et al., 2008), 
suggesting that in chronic lesions, OPCs are locally associated 
with astrocyte CXCL12 to enhance CXCR4 activation. Al-
though the mechanisms underlying CXCR4-mediated OPC 
maturation are poorly understood, growth factors, including 
brain-derived neurotropic factor (BDNF), may contribute to 
CXCR4 expression or activation, as exposure to BDNF ren-
ders OPCs responsive to CXCL12 (Xu and Heilshorn, 2013).
Current treatment modalities for MS primarily rely on 
immune suppression, which can lead to unfavorable side ef-
fects. Furthermore, we and others have shown that inflamma-
tory mediators, like tumor necrosis factor , promote CNS 
repair (Arnett et al., 2001; Patel et al., 2012). Importantly, we 
have demonstrated that the use of a CXCR7 antagonist dur-
ing demyelination has proven beneficial not only in the con-
text of repair, as shown here, but also during immune-mediated 
CNS injury, while leaving immune cell function largely intact 
(Cruz-Orengo et al., 2011b). Together, these data emphasize 
the potential efficacy of CXCR7 antagonism during initial in-
flammatory events as well as during recovery in MS patients.
MATERIALS AND METHODS
Mouse model of CPZ-mediated demyelination. 8-wk-old male 
C57BL/6 or CXCR7GFP/+ mice were fed a standard diet (Harlan) containing 
0.2% CPZ (Sigma-Aldrich) for 3–6 wk. For the induction of remyelination, 
CPZ-infused feed was removed and animals were given standard chow for 
10 d. All animal studies were performed in accordance with the Animal Care 
and Use Committee guidelines of the National Institutes of Health and were 
conducted under protocols approved by the Animal Care and Use Commit-
tee of Washington University.
Antibodies. The following antibodies were used in this study: anti-MBP 
(1:100; Abcam), -MBP69-86 (1:2000; Millipore), -GFP (1:1,000; Invitrogen), 
-CXCR4 (1:50; Abcam), -CXCL12 (1:20; eBioscience), -NG2 (1:100; Milli-
pore), -GFAP (1:200; Invitrogen), –Iba-1 (1:250; Wako), -CD31 (1:20; BD), 
–neurofilament heavy chain (NFH; 1:500; Aves), –phospho-339S-CXCR4 
(1:50; Abcam), -PDGFR (1:50; Millipore), -GST (1:1,000; Assay Designs), 
-BrdU (1:100; Sigma-Aldrich), and -MOG (1:100; R&D Systems).
Immunohistochemistry. Frozen sections were prepared and detection of 
cell markers were accomplished as previously described (Patel et al., 2010, 
2012). In brief, tissue sections were blocked with goat serum and Triton X-100 
(Sigma-Aldrich) for 1 h at room temperature and then exposed to primary 
treatments and allowed mice to remyelinate for 10 d (Fig. 4 A). 
After the remyelination phase, mice treated with the CXCR7 
antagonist had increased MOG expression and GST+ cells 
within the CC compared with those treated with vehicle 
(Fig. 4 B). To determine if the increased myelin expression 
observed during CXCR7 blockade was due to increased 
CXCR4 activation (Fig. 3), mice were continuously adminis-
tered the specific CXCR4 antagonist AMD3100 versus sa-
line vehicle for 10 d after the cessation of CPZ and CCX771 
(Fig. 4 A). As expected, during remyelination of the CC, mice 
treated with CCX771, followed by vehicle, exhibited similar 
oligodendrocyte maturation patterns as those treated with 
CCX771 alone. However, when mice were additionally treated 
with AMD3100 during remyelination, levels of MOG ex-
pression and numbers of GST+ cells were similar to mice 
treated with vehicle (Fig. 4 B). Furthermore, we determined 
that increased remyelination correlated with phosphorylation 
of CXCR4 (Fig. 4 B). Remyelination was confirmed using 
eriochrome cyanine staining of coronal sections of the CC 
(Fig. 4 C). Toluidine blue staining of sagittal sections of the 
CC additionally revealed the increased presence of new my-
elin in CCX771-treated mice (Fig. 4 D, yellow arrows) in com-
parison with those of vehicle-treated mice, which contained 
more demyelinated axons (Fig. 4 D, red arrows). Collectively, 
these data suggest that CXCR4-dependent remyelination in 
the adult CNS is enhanced after CXCR7 antagonism.
Repair of demyelinated lesions is necessary to prevent ir-
reversible neurological disability in MS patients and requires 
the proliferation and maturation of OPCs within the CNS. 
Several potential targets for promoting myelination have been 
described; however, here, for the first time, we were able to 
therapeutically enhance remyelination after CNS injury using a 
small molecule inhibitor to prompt activation of development-
like chemokine networks.
The up-regulation of CXCR7 exclusively during demye-
lination is consistent with its role in tightly regulating CXCR4 
activity in response to extracellular CXCL12 during CNS in-
sult. In other CNS injury models, including cerebral ischemia, 
CXCR7 mRNA was elevated in neurons after middle cerebral 
artery occlusion and was undetectable once tissue degenera-
tion was complete and cell-based regeneration was initiated 
(Schönemeier et al., 2008). Widespread expression of CXCR7 
suggests that the regulation of CXCL12 availability is critical 
for the function of CXCR4. During neuroinflammation, 
CXCR4 is expressed on neural progenitor cells and facilitates 
migration to sites of pathology, namely via directed expression 
of CXCL12 on the surface of astrocytes and CNS endothelial 
cells (Imitola et al., 2004). The interplay of the two CXCL12 
receptors during OPC maturation becomes evident as CXCR7 
protein expression increases while CXCR4 expression decreases 
during differentiation (Göttle et al., 2010), indicating that 
CXCR7 has an opposing, and likely regulatory, role in CXCR4-
mediated OPC maturation.
In a viral model of demyelination, CXCR4 signaling was 
indispensable for OPC proliferation and enhanced remyelin-
ation (Carbajal et al., 2011). Furthermore, AMD3100 treatment 
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Statistical analysis. Data were analyzed using Prism (GraphPad Software). 
An unpaired Student’s t test or one-way ANOVA was used to determine 
statistical significance. Data are expressed as means ± SEM. Sample sizes are 
indicated in the figure legends.
The authors thank Megan Muccigrosso and Bryan Bollman for technical assistance 
and Mark Penfold (ChemoCentryx) for CCX771.
This study was supported by the W.M. Keck Fellowship in Molecular Medicine 
(J.L. Williams), the National Institutes of Health/National Institute of Neurological 
Disorders and Stroke Grant P01 NS059560 (R.S. Klein), and grants from the National 
Multiple Sclerosis Society (R.S. Klein).
The authors declare no competing financial interests.
Submitted: 11 June 2013
Accepted: 19 March 2014
REFERENCES
Arnett, H.A., J. Mason, M. Marino, K. Suzuki, G.K. Matsushima, and J.P. Ting. 
2001. TNF promotes proliferation of oligodendrocyte progenitors and 
remyelination. Nat. Neurosci. 4:1116–1122. http://dx.doi.org/10.1038/ 
nn738
Bajetto, A., R. Bonavia, S. Barbero, P. Piccioli, A. Costa, T. Florio, and G. Schettini. 
1999. Glial and neuronal cells express functional chemokine receptor 
CXCR4 and its natural ligand stromal cell-derived factor 1. J. Neurochem. 
73:2348–2357. http://dx.doi.org/10.1046/j.1471-4159.1999.0732348.x
Banisadr, G., D. Skrzydelski, P. Kitabgi, W. Rostène, and S.M. Parsadaniantz. 
2003. Highly regionalized distribution of stromal cell-derived factor-1/
CXCL12 in adult rat brain: constitutive expression in cholinergic, dopa-
minergic and vasopressinergic neurons. Eur. J. Neurosci. 18:1593–1606. 
http://dx.doi.org/10.1046/j.1460-9568.2003.02893.x
Boldajipour, B., H. Mahabaleshwar, E. Kardash, M. Reichman-Fried, H. Blaser, 
S. Minina, D. Wilson, Q. Xu, and E. Raz. 2008. Control of chemokine-
guided cell migration by ligand sequestration. Cell. 132:463–473. http://
dx.doi.org/10.1016/j.cell.2007.12.034
Calderon, T.M., E.A. Eugenin, L. Lopez, S.S. Kumar, J. Hesselgesser, C.S. 
Raine, and J.W. Berman. 2006. A role for CXCL12 (SDF-1) in the 
pathogenesis of multiple sclerosis: regulation of CXCL12 expression in 
astrocytes by soluble myelin basic protein. J. Neuroimmunol. 177:27–39. 
http://dx.doi.org/10.1016/j.jneuroim.2006.05.003
Carbajal, K.S., C. Schaumburg, R. Strieter, J. Kane, and T.E. Lane. 2010. 
Migration of engrafted neural stem cells is mediated by CXCL12 signaling 
through CXCR4 in a viral model of multiple sclerosis. Proc. Natl. Acad. Sci. 
USA. 107:11068–11073. http://dx.doi.org/10.1073/pnas.1006375107
Carbajal, K.S., J.L. Miranda, M.R. Tsukamoto, and T.E. Lane. 2011. CXCR4 
signaling regulates remyelination by endogenous oligodendrocyte pro-
genitor cells in a viral model of demyelination. Glia. 59:1813–1821. 
http://dx.doi.org/10.1002/glia.21225
Chang, A., A. Nishiyama, J. Peterson, J. Prineas, and B.D. Trapp. 2000. NG2-
positive oligodendrocyte progenitor cells in adult human brain and mul-
tiple sclerosis lesions. J. Neurosci. 20:6404–6412.
Chang, A., W.W. Tourtellotte, R. Rudick, and B.D. Trapp. 2002. Premyelinating 
oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med. 
346:165–173. http://dx.doi.org/10.1056/NEJMoa010994
Compston, A., and A. Coles. 2002. Multiple sclerosis. Lancet. 359:1221–1231. 
http://dx.doi.org/10.1016/S0140-6736(02)08220-X
Cruz-Orengo, L., Y.J. Chen, J.H. Kim, D. Dorsey, S.K. Song, and R.S. Klein. 
2011a. CXCR7 antagonism prevents axonal injury during experimen-
tal autoimmune encephalomyelitis as revealed by in vivo axial diffusivity. 
J. Neuroinflammation. 8:170. http://dx.doi.org/10.1186/1742-2094-8-170
Cruz-Orengo, L., D.W. Holman, D. Dorsey, L. Zhou, P. Zhang, M. Wright, 
E.E. McCandless, J.R. Patel, G.D. Luker, D.R. Littman, et al. 2011b. 
CXCR7 influences leukocyte entry into the CNS parenchyma by con-
trolling abluminal CXCL12 abundance during autoimmunity. J. Exp. 
Med. 208:327–339. http://dx.doi.org/10.1084/jem.20102010
Dziembowska, M., T.N. Tham, P. Lau, S. Vitry, F. Lazarini, and M. Dubois-
Dalcq. 2005. A role for CXCR4 signaling in survival and migration of 
neural and oligodendrocyte precursors. Glia. 50:258–269. http://dx.doi 
.org/10.1002/glia.20170
antibody overnight at 4°C. For MBP and pCXCR4 labeling, we used an anti-
gen retrieval solution consisting of 0.1% trypsin and 0.1% CaCl in 0.05 M 
Tris, pH 7.4, and 10 mM citrate buffer, pH 6.0, respectively, at 37°C for 
10 min, and for BrdU labeling, 1 M HCl was applied to tissue sections for 
25 min at 45°C. Secondary antibodies conjugated to Alexa Fluor 488 or Alexa 
Fluor 555 (Molecular Probes) were applied for 1 h at room temperature. 
Nuclei were counterstained with ToPro3 (Molecular Probes) diluted in PBS. 
Sections were analyzed using the 40× objective of a confocal laser-scanning 
microscope (LSM 510 META; Carl Zeiss). The mean positive area and inten-
sity thresholds were determined using appropriate isotype control antibodies 
and were quantified using AxioVision (Carl Zeiss) and Volocity (Perkin 
Elmer) image analysis software.
In vivo BrdU incorporation. 50 mg/kg BrdU (Sigma-Aldrich) in PBS 
was injected i.p. every 8 h for 4 d as previously described (Arnett et al., 2001; 
Patel et al., 2012).
In vivo CCX771 and AMD3100 treatment. 30 mg/kg CCX771 (Che-
moCentryx) or vehicle (10% Captisol) was administered daily (s.c.) in 100 µl 
vehicle throughout the treatment period. Continuous dose treatment of 
AMD3100 (50 µg/h; Sigma-Aldrich) or saline was achieved using 14-d os-
motic pumps (Alzet) with an infusion rate of 0.25 µl/h as previously described 
(Patel et al., 2010).
Histology. For eriochrome cyanine staining, frozen sections of the CC were 
rehydrated in PBS, followed by dH2O and stained with Eriochrome cyanine R 
(Sigma-Aldrich) for 10 min. Tissue was then rinsed in tap water for 5 min 
and differentiated in 10% iron alum (Sigma-Aldrich). Sections were then 
counterstained with van Gieson stain, washed, and dehydrated before visual-
ization. For toluidine blue staining, brains were immersion fixed in 2% PFA 
and 2.5% glutaraldehyde in 0.1 M sodium cacodylate, pH 7.4. A 1.0-mm 
cube of the caudal CC was dissected and washed in 0.1 M sodium cacodylate 
overnight. Tissue was then fixed for 2 h in 1% osmium tetroxide and washed 
overnight in 0.1 M sodium cacodylate. The tissue was dehydrated in ethanol, 
infiltrated with 1:1 Spurr’s resin/100% ethanol, embedded in Spurr’s resin, 
allowed to polymerize for 48 h at 65°C, and sagittal 1-µm-thick sections were 
cut with a diamond knife. Sections were stained with toluidine blue for 1–2 min 
over heat, rinsed with tap water, and coverslips were applied.
Western blot. The caudal CC was dissected and 10 µg protein lysates were 
isolated using RIPA buffer supplemented with a protease and phosphatase-3 
inhibitor cocktail (Sigma-Aldrich). Lysates were resolved on a 4–12% Bis-
Tris gel and transferred onto an iBlot Nitrocellulose transfer membrane (In-
vitrogen) according to standard protocols. Blots were probed with polyclonal 
rabbit anti-CXCL12 (eBioscience) and monoclonal mouse anti–-tubulin 
(Sigma-Aldrich) antibodies, followed by incubation with IRDye-conjugated 
secondary antibodies (LI-COR). Blots were imaged using the Odyssey fluor-
escent scanning system (LI-COR) and analyzed using ImageJ (National 
Institutes of Health).
Quantitative PCR. Astrocytes were isolated from postnatal day 3 C57BL/6 
mouse pups as previously described (Patel et al., 2010). Cells were seeded in 
24-well plates until confluent and treated with DMSO or CCX771 for 24 h. 
Total RNA was isolated and quantitative real-time (qRT) PCR was per-
formed using primers for CXCL12 as previously described (McCandless 
et al., 2006).
In vitro CXCL12-mCherry internalization. Astrocytes were seeded in 
24-well plates until confluent and treated with DMSO or CCX771 for 2 h. 
CXCL12-mCherry fusion protein (Cruz-Orengo et al., 2011b) or recombi-
nant mCherry (BioVision) was then added to the cultures for 4 h. Cells were 
then washed with cold 0.5 M acetic acid wash buffer to remove surface bound 
CXCL12-mCherry, and then fixed with ice-cold 4% PFA. Astrocytes were then 
labeled with polyclonal rabbit anti-DsRed (1:200; Takara Bio Inc.) and counter-
stained with ToPro3 as previously described (Cruz-Orengo et al., 2011b).
 o
n
 M
ay 21, 2014
jem.rupress.org
D
ow
nloaded from
 
Published April 14, 2014
JEM Vol. 211, No. 5 799
Br ief Definit ive Repor t
Franklin, R.J., and C. Ffrench-Constant. 2008. Remyelination in the CNS: 
from biology to therapy. Nat. Rev. Neurosci. 9:839–855. http://dx.doi.org/ 
10.1038/nrn2480
Göttle, P., D. Kremer, S. Jander, V. Odemis, J. Engele, H.P. Hartung, and P. Küry. 
2010. Activation of CXCR7 receptor promotes oligodendroglial cell mat-
uration. Ann. Neurol. 68:915–924. http://dx.doi.org/10.1002/ana.22214
Hatse, S., K. Princen, G. Bridger, E. De Clercq, and D. Schols. 2002. 
Chemokine receptor inhibition by AMD3100 is strictly confined to 
CXCR4. FEBS Lett. 527:255–262. http://dx.doi.org/10.1016/S0014- 
5793(02)03143-5
Imitola, J., K. Raddassi, K.I. Park, F.J. Mueller, M. Nieto, Y.D. Teng, D. Frenkel, 
J. Li, R.L. Sidman, C.A. Walsh, et al. 2004. Directed migration of neu-
ral stem cells to sites of CNS injury by the stromal cell-derived fac-
tor 1/CXC chemokine receptor 4 pathway. Proc. Natl. Acad. Sci. USA. 
101:18117–18122. http://dx.doi.org/10.1073/pnas.0408258102
Klein, R.S., and J.B. Rubin. 2004. Immune and nervous system CXCL12 
and CXCR4: parallel roles in patterning and plasticity. Trends Immunol. 
25:306–314. http://dx.doi.org/10.1016/j.it.2004.04.002
Kuhlmann, T., V. Miron, Q. Cui, C. Wegner, J. Antel, and W. Brück. 2008. 
Differentiation block of oligodendroglial progenitor cells as a cause for 
remyelination failure in chronic multiple sclerosis. Brain. 131:1749–1758. 
http://dx.doi.org/10.1093/brain/awn096
Lindner, M., S. Heine, K. Haastert, N. Garde, J. Fokuhl, F. Linsmeier, C. Grothe, 
W. Baumgärtner, and M. Stangel. 2008. Sequential myelin protein ex-
pression during remyelination reveals fast and efficient repair after central 
nervous system demyelination. Neuropathol. Appl. Neurobiol. 34:105–114.
Matsuo, A., G.C. Lee, K. Terai, K. Takami, W.F. Hickey, E.G. McGeer, and P.L. 
McGeer. 1997. Unmasking of an unusual myelin basic protein epitope 
during the process of myelin degeneration in humans: a potential mech-
anism for the generation of autoantigens. Am. J. Pathol. 150:1253–1266.
McCandless, E.E., Q. Wang, B.M. Woerner, J.M. Harper, and R.S. Klein. 2006. 
CXCL12 limits inflammation by localizing mononuclear infiltrates to 
the perivascular space during experimental autoimmune encephalomy-
elitis. J. Immunol. 177:8053–8064.
McCandless, E.E., L. Piccio, B.M. Woerner, R.E. Schmidt, J.B. Rubin, A.H. 
Cross, and R.S. Klein. 2008. Pathological expression of CXCL12 at the 
blood-brain barrier correlates with severity of multiple sclerosis. Am. J. 
Pathol. 172:799–808. http://dx.doi.org/10.2353/ajpath.2008.070918
Naumann, U., E. Cameroni, M. Pruenster, H. Mahabaleshwar, E. Raz, H.G. 
Zerwes, A. Rot, and M. Thelen. 2010. CXCR7 functions as a scaven-
ger for CXCL12 and CXCL11. PLoS ONE. 5:e9175. http://dx.doi 
.org/10.1371/journal.pone.0009175
Patel, J.R., E.E. McCandless, D. Dorsey, and R.S. Klein. 2010. CXCR4 pro-
motes differentiation of oligodendrocyte progenitors and remyelination. 
Proc. Natl. Acad. Sci. USA. 107:11062–11067. http://dx.doi.org/10.1073/ 
pnas.1006301107
Patel, J.R., J.L. Williams, M.M. Muccigrosso, L. Liu, T. Sun, J.B. Rubin, and 
R.S. Klein. 2012. Astrocyte TNFR2 is required for CXCL12-mediated 
regulation of oligodendrocyte progenitor proliferation and differentia-
tion within the adult CNS. Acta Neuropathol. 124:847–860. http://dx.doi 
.org/10.1007/s00401-012-1034-0
Schönemeier, B., S. Schulz, V. Hoellt, and R. Stumm. 2008. Enhanced expression 
of the CXCl12/SDF-1 chemokine receptor CXCR7 after cerebral isch-
emia in the rat brain. J. Neuroimmunol. 198:39–45. http://dx.doi.org/10 
.1016/j.jneuroim.2008.04.010
Steinman, L. 2009. A molecular trio in relapse and remission in multiple sclero-
sis. Nat. Rev. Immunol. 9:440–447. http://dx.doi.org/10.1038/nri2548
Wolswijk, G. 1998. Chronic stage multiple sclerosis lesions contain a relatively 
quiescent population of oligodendrocyte precursor cells. J. Neurosci. 
18:601–609.
Xu, H., and S.C. Heilshorn. 2013. Microfluidic investigation of BDNF- 
enhanced neural stem cell chemotaxis in CXCL12 gradients. Small. 9: 
585–595. http://dx.doi.org/10.1002/smll.201202208
Zhu, Y., T. Matsumoto, S. Mikami, T. Nagasawa, and F. Murakami. 2009. 
SDF1/CXCR4 signalling regulates two distinct processes of precerebel-
lar neuronal migration and its depletion leads to abnormal pontine nuclei 
formation. Development. 136:1919–1928. http://dx.doi.org/10.1242/ 
dev.032276
Zou, Y.R., A.H. Kottmann, M. Kuroda, I. Taniuchi, and D.R. Littman. 1998. 
Function of the chemokine receptor CXCR4 in haematopoiesis and 
in cerebellar development. Nature. 393:595–599. http://dx.doi.org/10 
.1038/31269
 o
n
 M
ay 21, 2014
jem.rupress.org
D
ow
nloaded from
 
Published April 14, 2014
